Angion Biomedica Corp. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
3Angion Biomedica's Business Model
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
About Angion Biomedica
Website: https://www.angion.com
CEO (Chief Executive Officer): Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
IPO date: 2021-02-05
Contact
Country: US
Address: 51 Charles Lindbergh Boulevard
City: Uniondale
State: NY
Phone: 415 655 4899
Zip Code: 11553
Other
CIK: 0001601485
ISIN: US03476J1079
CUSIP: 03476J107
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
